Search results | array biopharma

Reports

Partnering Agreements with Array Biopharma

The Partnering Agreements with Array Biopharma report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Insights

Array BioPharma: Company profile

Array BioPharma, a top big biotech company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Current Agreements Deal Analysis Update : June 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.

Celgene; Going ‘green’ for transformative technologies

Celgene is a big pharmaceutical company discovering and developing medical treatments indicated for cancer and other inflammatory conditions.

Current Agreements Deals Update: September 2011

Welcome to the September 2011 edition of Current Agreements Deals Update

Aspen Pharmacare – Africa’s biggest generic drugmaker

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

Partnering with Pfizer: Collaborating to give hope

Pfizer is a top pharma company active in partnering, licensing and M&A in pharmaceuticals

Events

Sorry, your search returned no results.


Deals

Array Biopharma acquires encorafenib rights from Novartis

Array BioPharma has reached a definitive agreement with Novartis Pharma to acquire worldwide rights to encorafenib

Array BioPharma signs licensing deal with Oncothyreon

Array BioPharma has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor.

Array Biopharma regains binimetinib from Novartis

Array BioPharma has reached a definitive agreement with Novartis to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials

Array biopharma partners with Celgene for inflammation pathway

Array BioPharma partners with Celgene Corporation for an Array-invented preclinical development program targeting a novel inflammation pathway

Loxo Oncology pharma deals Array Biopharma for novel oncology drug collaboration and licensing

Loxo Oncology pharma deals Array BioPharma for multi-year license and collaboration agreement for developing novel oncology drugs.

Array Biopharma creates financing news with $100 million direct offering

Array BioPharma plans to offer in financing, subject to market and other conditions, convertible senior notes due 2020 of approximately $100 million in aggregate principal amount in an underwritten public offering financing

Array BioPharma announces public offering of common stock for $65.7 million

Array BioPharma undertook a financing venture and announced the pricing of an underwritten public offering of 18,000,000 primary shares of its common stock at a public offering price of $3.65 per share

Array BioPharma announces public offering for common stock

Array BioPharma announced the pricing of an underwritten public offering of 20,000,000 primary shares of its common stock at a public offering price of $2.60 per share.

Array BioPharma and Amgen partner in type 2 diabetes

Agreement granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.

Gilead and Cancer Genetics are biopharma partners

Cancer Genetics and Gilead Sciences, a big pharma company, are now biopharma partners where Cancer Genetics is providing clinical trial services and molecular profiling of chronic lymphocytic leukemia patients.